Search

Your search keyword '"Lampropoulos K"' showing total 98 results
Start Over Author "Lampropoulos K"
98 results on '"Lampropoulos K"'

3. An Intermediate Framework for Unifying and Automating Mobile Communication Systems

Author

Koumoutsos, G., Lampropoulos, K., Efthymiopoulos, N., Christakidis, A., Denazis, S., Thramboulidis, K., Hutchison, David, editor, Kanade, Takeo, editor, Kittler, Josef, editor, Kleinberg, Jon M., editor, Mattern, Friedemann, editor, Mitchell, John C., editor, Naor, Moni, editor, Nierstrasz, Oscar, editor, Pandu Rangan, C., editor, Steffen, Bernhard, editor, Sudan, Madhu, editor, Terzopoulos, Demetri, editor, Tygar, Dough, editor, Vardi, Moshe Y., editor, Weikum, Gerhard, editor, Gaïti, Dominique, editor, Pujolle, Guy, editor, Al-Shaer, Ehab, editor, Calvert, Ken, editor, Dobson, Simon, editor, Leduc, Guy, editor, and Martikainen, Olli, editor

Published
2006
Full Text
View/download PDF

4. DEEP LEARNING APPROACH FOR THE IDENTIFICATION OF STRUCTURAL LAYERS IN HISTORIC MONUMENTS FROM GROUND PENETRATING RADAR IMAGES

Author

Alexakis, E., Lampropoulos, K., Doulamis, N., Doulamis, A., and Moropoulou, A.

Subjects
Deep Learning, radagram, Artificial Intelligence, GPR, Computer Vision, Holy Sepulchre, Image Segmentation, Ground Penetrating Radar, U-net
Abstract

The present work is about the application of Artificial Intelligence and in particular Computer Vision approaches for the analysis and classification of Ground Penetrating Radar (GPR) B-Scan radargrams gathered during a GPR data acquisition campaign for the diagnostic study, for the assessment of the preservation state of the Holy Aedicule of the Holy Sepulchre in Jerusalem. The analysis of those data revealed the Aedicule’s structural layers and most important indicated the cause of the historical building pathology. The objective of this study is to extract the knowledge coming from the typical analysis of B-can radargrams, based on which the various structural layers derived, omitting this way several manual data pre-processing and time-consuming steps. The study employs a Deep Learning architecture, known as U-Net, where an image segmentation approach has been followed to build and train a classifier able to discriminate the various structural layers detected by the original measurements of radargrams.

Published
2022
Full Text
View/download PDF

5. Artificial intelligence supporting cancer patients across Europe—The ASCAPE project

Author

Tzelves, L. Manolitsis, I. Varkarakis, I. Ivanovic, M. Kokkonidis, M. Useros, C.S. Kosmidis, T. Muñoz, M. Grau, I. Athanatos, M. Vizitiu, A. Lampropoulos, K. Koutsouri, T. Stefanatou, D. Perrakis, K. Stratigaki, C. Autexier, S. Kosmidis, P. Valachis, A.

Subjects
humanities
Abstract

Introduction Breast and prostate cancer survivors can experience impaired quality of life (QoL) in several QoL domains. The current strategy to support cancer survivors with impaired QoL is suboptimal, leading to unmet patient needs. ASCAPE aims to provide personalized- and artificial intelligence (AI)-based predictions for QoL issues in breast- and prostate cancer patients as well as to suggest potential interventions to their physicians to offer a more modern and holistic approach on cancer rehabilitation. Methods and analyses An AI-based platform aiming to predict QoL issues and suggest appropriate interventions to clinicians will be built based on patient data gathered through medical records, questionnaires, apps, and wearables. This platform will be prospectively evaluated through a longitudinal study where breast and prostate cancer survivors from four different study sites across the Europe will be enrolled. The evaluation of the AI-based follow-up strategy through the ASCAPE platform will be based on patients’ experience, engagement, and potential improvement in QoL during the study as well as on clinicians’ view on how ASCAPE platform impacts their clinical practice and doctor-patient relationship, and their experience in using the platform. Ethics and dissemination ASCAPE is the first research project that will prospectively investigate an AI-based approach for an individualized follow-up strategy for patients with breast- or prostate cancer focusing on patients’ QoL issues. ASCAPE represents a paradigm shift both in terms of a more individualized approach for follow-up based on QoL issues, which is an unmet need for cancer survivors, and in terms of how to use Big Data in cancer care through democratizing the knowledge and the access to AI and Big Data related innovations. Trial registration Trial Registration on clinicaltrials.gov: NCT04879563. © 2022 Tzelves et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Published
2022

6. Routine podiatry assessment as a potential preventive tool for atrial fibrillation screening in diabetics

Author

Petridou, M, primary, Matopoulou, E, additional, Kanellos, I, additional, Daios, S, additional, Patrikios, I, additional, Charalampous, K, additional, Lampropoulos, K, additional, Stefanou, A, additional, Skantzis, P, additional, Arkouli, V, additional, Papaioannou, N, additional, Papaioannou, G, additional, Kaiafa, G, additional, Savopoulos, C, additional, and Papaioannou, S, additional

Published
2021
Full Text
View/download PDF

7. Association of QT dispersion with mortality and arrhythmic events—A meta-analysis of observational studies

Author

Bazoukis, G. Yeung, C. Wui Hang Ho, R. Varrias, D. Papadatos, S. Lee, S. Ho Christien Li, K. Sakellaropoulou, A. Saplaouras, A. Kitsoulis, P. Vlachos, K. Lampropoulos, K. Thomopoulos, C. Letsas, K.P. Liu, T. Tse, G.

Subjects
cardiovascular diseases
Abstract

Background: The risk stratification of coronary heart disease (CHD) and/or heart failure (HF) patients with easily measured electrocardiographic markers is of clinical importance. The aim of this meta-analysis is to indicate whether increased QT dispersion (QTd) is associated with fatal and nonfatal outcomes in patients with CHD and/or HF. Methods: We systematically searched MEDLINE and Cochrane databases without restrictions until August 15, 2018 using the keyword “QT dispersion”. Studies including data on the association between QTd and all-cause mortality, sudden cardiac death (SCD) or arrhythmic events in patients with HF and/or CHD were classified as eligible. Results: In the analysis including patients with CHD and/or HF, we found that QTd did not differ significantly in patients with SCD compared to no SCD patients while QTd was significantly greater in the group of all-cause mortality patients and in patients who experienced a sustained ventricular arrhythmia. Subgroup analysis showed that in myocardial infarction studies, QTd was significantly higher in patients with an arrhythmic event compared to arrhythmic event-free patients while a nonsignificant difference was found in QTd in patients who died from any cause compared to survivors. Similarly, in HF patients, the QTd was significantly greater in patients with an arrhythmic event while a nonsignificant difference was found regarding all-cause mortality and SCD outcomes. Conclusions: QTd has a prognostic role for stratifying myocardial infarction or HF patients who are at higher risk of arrhythmic events. However, no prognostic role was found regarding all-cause mortality or SCD in this patient population. © 2019 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.

Published
2020

9. Contemporary Presentation and Management of Valvular Heart Disease The EURObservational Research Programme Valvular Heart Disease II Survey

Author

Iung, B., Delgado, V., Rosenhek, R., Price, S., Prendergast, B., Wendler, O., Bonis, M. de, Tribouilloy, C., Evangelista, A., Bogachev-Prokophiev, A., Apor, A., Ince, H., Laroche, C., Popescu, B.A., Pierard, L., Haude, M., Hindricks, G., Ruschitzka, F., Windecker, S., Bax, J.J., Maggioni, A., Vahanian, A., Mekhaldi, S., Lemaitre, K., Authier, S., Druais, H., Goda, A., Mascherbauer, J., Samadov, F., Pasquet, A., Linhartova, K., Ihlemann, N., Abdelhamid, M., Saraste, A., Kostovska, E.S., Bajraktari, G., Mirrakhimov, E., Erglis, A., Mizariene, V., Cassar, D., Tomkiewicz-Pajak, L., Ribeiras, R., Popescu, B., Beleslin, B., Simkova, I., Dogan, S.M., Rahman-Haley, S., Shirka, E., Dado, E., Zera, E., Bica, L., Heger, M., Muslumova, F., Jahangirov, T., Ahmedov, T., Husseynov, S., Cosyns, B., Camp, G. van, Sindelarova, S., Branny, M., Parenicova, I., Vondrackova, D.J., Homza, M., Ostransky, J., Hasan-Ali, H., Abdelhady, Y., Hassan, M., Soliman, H., Mostafa, A.E., Moaaz, M., Kazamel, G., Sadek, Y., Eltobgi, S., Kamal, D., Kylmala, M., Turpeinen, A., Monin, J.L., Jobic, Y., Attias, D., Magne, J., Marechaux, S., Donal, E., Biere, L., Bernard, A., Daudin, M., Khounlaboud, M., Habib, G., Bardet, H., Audonnet, M., Thuny, F., Plurien, F., Berenfeld, A., Gervais, R., Sorbets, E., Charbonnier, A., Bauer, F., Menager-Gangloff, C., Gjerakorska-Radovikj, M., Jordanova, S., Caglayan, E., Hambrecht, R., Akin, I., Maier, L., Nickenig, G., Scholtz, W., Schulze, P.C., Heintzen, M., Er, F., Sigusch, H., Spargias, K., Kamperidis, V., Sachpekidis, V., Bellos, V., Kanakakis, I., Papafaklis, M., Makris, A., Poulimenos, L., Katsaros, A., Lampropoulos, K., Bartha, E., Zsary, A., Jebelovszki, E., Cziraki, A., Borsanyi, T., Lupkovics, G., Jarai, Z., Ibrahimi, P., Arapova, R., Laahunova, E., Sime, I., Rancane, G., Radauskaite, G., Raugaliene, R., Xuereb, R.G., Djaberi, R., Komar, M., Szymanski, P., Zaborska, B., Mizia-Stec, K., Regulski, M., Bogacki, P., Sedziwy, E., Komor, K., Myszor, J., Joao, I., Martins, R., Cabral, S., Gago, P., Cardoso, G., Almeida, I., Antunes, N., Carvalho, S., Galrinho, A., Freitas, A., Grigorica, L., Mitre, A., Ionac, A., Tint, D., Popescu, A., Petris, A.O., Onut, R., Pop, C., Usurelu, C., Beyer, R., Militaru, C., Eminovici, G., Arsenescu-Georgescu, C., Irtyuga, O., Semenova, E., Boldyrev, S., Kozmin, D., Gross, Y., Zotov, A., Kuznetsov, D., Nemchenko, E., Kulumbegov, O., Jakubov, R., Stefanov, S., Schneider, Y., Tsechanovich, V., Gamzaev, A., Fomenko, M., Mayorova, O., Skripkina, E., Safina, V., Slastin, Y., Koroleva, T., Polyaeva, L., Tarasenko, I., Alekseeva, S., Magamet, V., Medvedev, I., Khilova, L., Verevetinov, A., Stojsic-Milosavljevic, A., Nikolic, N.M., Ostric, D.K., Ruzicic, D., Pavlovic, S., Milosavljevic, J., Jovovic, L., Margoczy, R., Valocik, G., Studencan, M., Iglesias, F.C., Mendez, I., Gomez, A.G., Sanchez Fernandez, P.L., Valenzuela, G.M., Cladellas, M., Villegas, D.V., Moral, S., Gallego, I.M., Paya, R., Caballero, L., Paton, R.R., Esteban, E., Iglesia-Carreno, C., Alberca, M.T., Valle, A., Molina-Mora, M.J., Castro, N., Sayar, N., Demirtas, A.O., Yesilay, A., Demir, S., Bozkurt, A., Kanar, B., Gudul, N.E., Yildirim, T., Taylan, G., Mert, K.U., Yilmaztepe, M.A., Mert, G.O., Cosansu, K., Sayin, M.R., Karabag, T., EORP VHD II Investigators, Instituto Universitario de Investigacion de Nanocienca de Aragon, University of Zaragoza - Universidad de Zaragoza [Zaragoza], Instituto de Física de Cantabria (IFCA), Universidad de Cantabria [Santander]-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Leibniz Institute for Astrophysics Potsdam (AIP), St. Josef Hospital, Ruhr-University Bochum, Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM), Leiden University Medical Center (LUMC), Universiteit Leiden, Medizinische Universität Wien = Medical University of Vienna, Department of Imaging Royal Brompton Hospital, Royal Brompton Hospital, Guy's and St Thomas' Hospital [London], CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Vall d'Hebron University Hospital [Barcelona], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Liège (CHU-Liège), Lukaskrankenhaus, Universität Leipzig, University Heart Centre Freiburg - Bad Krozingen, Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri] (ANMCO Research Center), Associazione Nazionale Medici Cardiologi Ospedalieri [Firenze] (ANMCO), Service de cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Uppsala University, SAFRAN Group, Laboratory of In Vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel (VUB), Université de Lille, Sciences et Technologies, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes - Faculté de Médecine (UR Médecine), Université de Rennes (UR), CHU Pontchaillou [Rennes], Laboratoire de Protection et Remodelage du Myocarde (PMRM), Université d'Angers (UA)-Université d'Angers (UA), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU de Saint-Brieuc, Hôpital Lapeyronie [Montpellier] (CHU), Assistance Publique - Hôpitaux de Marseille (APHM), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut de la Vision, Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, University of Latvia (LU), Dipartimento di Scienza dei Materiali = Department of Materials Science [Milano-Bicocca], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), MDM Laboratory, IMM-CNR, Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Réseaux épuration et qualité des eaux (UR REBX), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), King Abdullah University of Science and Technology (KAUST), INSTITUTO NACIONAL DE INVESTIGACAO AGRARIA E VETERINARIA VILA DO CONDE PRT, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Université de Médecine Carol Davila, Emergency Institute for Cardiovascular Diseases 'Prof. Dr. C.C. Iliescu' [Bucharest, Romania], Département Intelligence Ambiante et Systèmes Interactifs (DIASI), Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Department of photonics engineering, Danmarks Tekniske Universitet = Technical University of Denmark (DTU), Clinical sciences, Cardio-vascular diseases, Cardiology, Universität Leipzig [Leipzig], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 - Faculté de Médecine (UR1 Médecine), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Institut National de la Recherche Agronomique (INRA)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Paris-Sud - Paris 11 (UP11)-École pratique des hautes études (EPHE), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Università degli Studi di Milano-Bicocca [Milano] (UNIMIB), Technical University of Denmark [Lyngby] (DTU), Université d'Angers (UA), Iung, Bernard, Delgado, Victoria, Rosenhek, Raphael, Price, Susanna, Prendergast, Bernard, Wendler, Olaf, De Bonis, Michele, Tribouilloy, Christophe, Evangelista, Arturo, Bogachev-Prokophiev, Alexander, Apor, Astrid, Ince, Hüseyin, Laroche, Cécile, Popescu, Bogdan A, Piérard, Luc, Haude, Michael, Hindricks, Gerhard, Ruschitzka, Frank, Windecker, Stephan, Bax, Jeroen J, Maggioni, Aldo, and Vahanian, Alec

Subjects
Male, Time Factors, [SDV]Life Sciences [q-bio], 030204 cardiovascular system & hematology, heart valve diseases, valvular surgery, Cardiologists, 0302 clinical medicine, Time-to-Treatment/trends, Referral and Consultation/trends, Heart Valve Diseases/diagnosis, Medicine, echocardiography, 03.02. Klinikai orvostan, 030212 general & internal medicine, Prospective Studies, Practice Patterns, Physicians', 610 Medicine & health, Referral and Consultation, valvular heart disease, Middle Aged, Europe, Practice Guidelines as Topic, cardiovascular system, Healthcare Disparities/trends, transcatheter aortic valve replacement, Female, Guideline Adherence, Presentation (obstetrics), Cardiology and Cardiovascular Medicine, guideline, Cardiologists/trends, medicine.medical_specialty, transcatheter intervention, Clinical Decision-Making, Time-to-Treatment, Europe/epidemiology, 03 medical and health sciences, Physiology (medical), Guideline Adherence/trends, Humans, Healthcare Disparities, Intensive care medicine, Aged, business.industry, medicine.disease, Practice Patterns, Physicians'/trends, Health Care Surveys, business, aged, 80 and over, guidelines as topic
Abstract

Background: Valvular heart disease (VHD) is an important cause of mortality and morbidity and has been subject to important changes in management. The VHD II survey was designed by the EURObservational Research Programme of the European Society of Cardiology to analyze actual management of VHD and to compare practice with guidelines. Methods: Patients with severe native VHD or previous valvular intervention were enrolled prospectively across 28 countries over a 3-month period in 2017. Indications for intervention were considered concordant if the intervention was performed or scheduled in symptomatic patients, corresponding to Class I recommendations specified in the 2012 European Society of Cardiology and in the 2014 American Heart Association/American College of Cardiology VHD guidelines. Results: A total of 7247 patients (4483 hospitalized, 2764 outpatients) were included in 222 centers. Median age was 71 years (interquartile range, 62–80 years); 1917 patients (26.5%) were ≥80 years; and 3416 were female (47.1%). Severe native VHD was present in 5219 patients (72.0%): aortic stenosis in 2152 (41.2% of native VHD), aortic regurgitation in 279 (5.3%), mitral stenosis in 234 (4.5%), mitral regurgitation in 1114 (21.3%; primary in 746 and secondary in 368), multiple left-sided VHD in 1297 (24.9%), and right-sided VHD in 143 (2.7%). Two thousand twenty-eight patients (28.0%) had undergone previous valvular intervention. Intervention was performed in 37.0% and scheduled in 26.8% of patients with native VHD. The decision for intervention was concordant with Class I recommendations in symptomatic patients with severe single left-sided native VHD in 79.4% (95% CI, 77.1–81.6) for aortic stenosis, 77.6% (95% CI, 69.9–84.0) for aortic regurgitation, 68.5% (95% CI, 60.8–75.4) for mitral stenosis, and 71.0% (95% CI, 66.4–75.3) for primary mitral regurgitation. Valvular interventions were performed in 2150 patients during the survey; of them, 47.8% of patients with single left-sided native VHD were in New York Heart Association class III or IV. Transcatheter procedures were performed in 38.7% of patients with aortic stenosis and 16.7% of those with mitral regurgitation. Conclusions: Despite good concordance between Class I recommendations and practice in patients with aortic VHD, the suboptimal number in mitral VHD and late referral for valvular interventions suggest the need to improve further guideline implementation.

Published
2019

10. A Questionnaire Model for Cybersecurity Maturity Assessment for Critical Infrastructures

Author

Yigit Ozkan, B., Spruit, M, Fournaris, A., Lampropoulos, K., Tordera, E., Sub Natural Language Processing, Sub Organization and Information, Natural Language Processing, and Organization and Information

Subjects
Cybersecurity, Capability, Improvement, Assessment, Critical infrastructure
Abstract

Critical infrastructures are important assets for everyday life and wellbeing of the people. People can be effected dramatically if critical infrastructures are vulnerable and not protected against various threats. Given the increasing cybersecurity risks and the large impact that these risks may bring to the critical infrastructures, assessing and improving the cybersecurity capabilities of the service providers and the administrators is crucial for sustainability. This research aims to provide a questionnaire model for assessing and improving cybersecurity capabilities based on industry standards. Another aim of this research is to provide service providers and the administrators of the critical infrastructures a personalized guidance and an implementation plan for cybersecurity capability improvement.

Published
2019

11. Intracardiac echocardiography for percutaneous patent foramen ovale and atrial septal defect occlusion [Intrakardiale Echokardiographie bei perkutanem Verschluss eines offenen Foramen ovale und eines Vorhofseptumdefekts]

Author

Kavvouras, C. Vavuranakis, M. Vaina, S. Lampropoulos, K. Bazoukis, G. Tse, G. Tousoulis, D.

Subjects
human activities
Abstract

Background: Transesophageal echocardiography (TEE) plays a unique role in transcatheter closure of atrial septal defects (ASD) and patent foramen ovale (PFO). However, problems such as the need for general anesthesia, possible trauma from endotracheal intubation, presence of “blind spots,” and occasional inadequate imaging of some cardiac structures have necessitated better imaging techniques. Our study aimed to compare the findings of TEE during the initial diagnostic examination with those from intracardiac echocardiography (ICE) acquired during the interventional procedure. Methods: A total of 65 patients in whom TEE was used for the diagnosis of ASD or PFO were included. Of these, 40 patients (61.5%) had ASD with significant left to right shunt and 25 (38.5%) patients had PFO associated with transient ischemic attack or stroke. ICE imaging was performed under local anesthesia in all patients to guide interatrial communication closure. Results: ICE provided adequate views of the defects and surrounding structures during the various stages of device deployment. In eight patients (12.3%) an additional anatomical variation was detected. All patients had successful device implantation and were discharged 1 day after the procedure. Conclusion: ICE is a safe and high-quality imaging technique for guiding transcatheter ASD and PFO occlusion. Additionally, ICE can both facilitate device implantation and detect cardiac abnormalities that are not identified with TEE during the initial diagnostic investigation. © 2018, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Published
2019

12. A Questionnaire Model for Cybersecurity Maturity Assessment for Critical Infrastructures

Author

Sub Natural Language Processing, Sub Organization and Information, Natural Language Processing, Organization and Information, Yigit Ozkan, B., Spruit, M, Fournaris, A., Lampropoulos, K., Tordera, E., Sub Natural Language Processing, Sub Organization and Information, Natural Language Processing, Organization and Information, Yigit Ozkan, B., Spruit, M, Fournaris, A., Lampropoulos, K., and Tordera, E.

Published
2019

13. Threat Modeling the Cloud:An Ontology Based Approach

Author

Fournaris, A., Lampropoulos, K., Marin Tordera, E., Manzoor, S., Vateva-Gurova, T., Trapero, R., Suri, Neeraj, Fournaris, A., Lampropoulos, K., Marin Tordera, E., Manzoor, S., Vateva-Gurova, T., Trapero, R., and Suri, Neeraj

Abstract

Critical Infrastructures (CIs) such as e-commerce, energy, transportation, defense, monitoring etc., form the basis of the modern ICT society, and these CI’s increasingly utilize ICT services such as the Cloud to provide for scalable, robust and cost-efficient services. Consequently, the resilience of the CI is directly connected with the resilience of the underlying Cloud infrastructure. However, performing a Cloud threat analysis (TA) is a challenging task given the complex interconnection of underlying computing and communication services. Thus, the need is of a comprehensive TA approach that can holistically analyze the relation across system level requirements and Cloud vulnerabilities. We target achieving such a requirement based threat analysis by developing an ontology depicting the relations among actors involved in the Cloud ecosystem. The ontology comprehensively covers requirement specifications, interaction among the Cloud services and vulnerabilities violating the requirements. By mapping the ontology to a design structure matrix, our approach obtains security assessments from varied actor perspectives. We demonstrate the effectiveness of our approach by assessing the security of OpenStack, an open source Cloud platform, covering user requirements and services involved in Cloud operations.

Published
2019

14. Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis

Author

Lakhani, I, Gong, M, Wong, WT, Bazoukis, G, Lampropoulos, K, Wong, SH, Wu, WKK, Wong, MCS, Ong, KL, Liu, T, Tse, G, Lakhani, I, Gong, M, Wong, WT, Bazoukis, G, Lampropoulos, K, Wong, SH, Wu, WKK, Wong, MCS, Ong, KL, Liu, T, and Tse, G

Abstract

Background: Fibroblast growth factor 21 is a signalling protein involved in cell differentiation, morphogenesis, proliferation and metabolism. Recent studies have associated increased levels of FGF21 in the development of cardiovascular diseases, whereas others have reported no significant associations. Therefore, this systematic review and meta-analysis evaluated the value in predicting the risk of cardio-metabolic disorders and mortality. Methods: PubMed and EMBASE were searched until 5th September 2017 for studies that evaluated the roles of FGF21 levels in cardio-metabolic disorders. Results: A total of 183 and 301 entries were retrieved; 24 studies met the inclusion criteria. Four studies were identified by an additional search. Therefore, 28 studies were included in the final meta-analysis. High FGF21 levels significantly predicted the incidence of coronary artery disease (hazard ratio [HR]: 1.29; 95% confidence interval [CI]: 1.06–1.55; P < 0. 01; I2 = 48%) and the risk of metabolic syndrome (HR: 1.70, 95% CI: 1.35–2.15; P < 0.0001 I2 = 24%). In diabetes mellitus, FGF21 predicted disease incidence or progression (HR: 1.35, 95% CI: 1.06–1.72, P < 0.05, I2 = 69%) and worsening renal failure (HR: 1.06, 95% CI: 1.03–1.09, P < 0.0001, I2 = 47%). FGF21 also predicted all-cause mortality (HR: 3.00, 95% CI: 1.23–7.33; P < 0.05; I2 = 51%), and cardiovascular mortality (HR: 2.33, 95% CI: 1.08–4.99, P < 0.05, I2 = 75%). Conclusion: FGF21 significantly predicts the incidence of coronary artery disease, the risks of metabolic syndrome, diabetes mellitus and renal progression in diabetes. It also predicted all-cause and cardiovascular mortality.

Published
2018

18. MERGING GEOMETRIC DOCUMENTATION WITH MATERIALS CHARACTERIZATION AND ANALYSIS OF THE HISTORY OF THE HOLY AEDICULE IN THE CHURCH OF THE HOLY SEPULCHRE IN JERUSALEM

Author

Georgopoulos, A., primary, Lambrou, E., additional, Pantazis, G., additional, Agrafiotis, P., additional, Papadaki, A., additional, Kotoula, L., additional, Lampropoulos, K., additional, Delegou, E., additional, Apostolopoulou, M., additional, Alexakis, M., additional, and Moropoulou, A., additional

Published
2017
Full Text
View/download PDF

26. Poster session IV * Friday 10 December 2010, 14:00-18:00

Author

Mora, B., primary, Base, E., additional, Schmid, W., additional, Andreas, M., additional, Weber, U., additional, Junreitmaier, M., additional, Foerster, F., additional, Hiesmayr, M., additional, Tschernich, H. D., additional, Guldbrand, D., additional, Goetzsche, O., additional, Eika, B., additional, Fumagalli, S., additional, Francini, S., additional, Gabbai, D., additional, Pedri, S., additional, Casalone Rinaldi, M., additional, Makhanian, Y., additional, Sollami, R., additional, Tarantini, F., additional, Marchionni, N., additional, Azcarate, P. M., additional, Castano, S., additional, Rodriguez-Manero, M., additional, Arraiza, M., additional, Levy, B., additional, Barba, J., additional, Rabago, G., additional, Bastarrika, G., additional, Rus, H., additional, Radoi, M., additional, Ciurea, C., additional, Boda, D., additional, Erdei, T., additional, Denes, M., additional, Mihalcz, A., additional, Kardos, A., additional, Foldesi, C. S., additional, Temesvari, A., additional, Lengyel, M., additional, Cameli, M., additional, Lisi, M., additional, Righini, F., additional, Ballo, P., additional, Henein, M., additional, Mondillo, S., additional, Nistri, S., additional, Galderisi, M., additional, Ballo, P. C., additional, Pagliani, L., additional, Olivotto, I., additional, Santoro, A., additional, Papesso, B., additional, Innelli, P., additional, Cecchi, F., additional, Hristova, K., additional, Katova, T. Z., additional, Kostova, V., additional, Simova, Y., additional, Nesheva, N., additional, Ivanovic, B., additional, Tadic, M. T., additional, Simic, D. S., additional, Rao, C. M., additional, Aguglia, D., additional, Casciola, G., additional, Imbesi, C., additional, Marvelli, A., additional, Sgro, M., additional, Benedetto, D., additional, Tripepi, G., additional, Zoccali, C., additional, Benedetto, F. A., additional, Mantziari, L., additional, Kamperidis, V., additional, Damvopoulou, E., additional, Ventoulis, I., additional, Giannakoulas, G., additional, Paraskevaidis, S., additional, Vassilikos, V., additional, Karvounis, H., additional, Styliadis, I. H., additional, Sonder, T. K., additional, Loegstrup, B. B., additional, Lambrechtsen, J., additional, Van Bortel, L. M., additional, Segers, P., additional, Egstrup, K., additional, Tho, A., additional, Moceri, P., additional, Bertora, D., additional, Gibelin, P., additional, Cho, E. J., additional, Choi, K. Y., additional, Kim, B. J., additional, Kim, D. B., additional, Jang, S. W., additional, Park, C. S., additional, Jung, H. O., additional, Jeon, H. K., additional, Youn, H. J., additional, Kim, J. H., additional, Donal, E., additional, Coquerel, N., additional, Bodi, S., additional, Thebault, C., additional, Kervio, G., additional, Carre, F., additional, Daly, M. J., additional, Fairley, S. L., additional, Doherty, R., additional, Ashfield, K., additional, Kirkpatrick, R., additional, Smith, B., additional, Buchanan, J., additional, Hill, L., additional, Dixon, L. J., additional, Rosca, M., additional, O' Connor, K., additional, Magne, J., additional, Romano, G., additional, Calin, A., additional, Popescu, B. A., additional, Beladan, C. C., additional, Pierard, L., additional, Ginghina, C., additional, Lancellotti, P., additional, Bochenek, T., additional, Wita, K., additional, Tabor, Z., additional, Grabka, M., additional, Elzbieciak, M., additional, Trusz-Gluza, M., additional, Moreau, O., additional, Leclercq, C., additional, Sahlen, A., additional, Shahgaldi, K., additional, Aminoff, A., additional, Aagaard, P., additional, Manouras, A., additional, Winter, R., additional, Ehrenborg, E., additional, Braunschweig, F., additional, Bedetti, G., additional, Gargani, L., additional, Pizzi, C., additional, Sicari, R., additional, Picano, E., additional, Zhang, J., additional, Zhang, H. B., additional, Duan, Y. Y., additional, Chen, L. L., additional, Li, J., additional, Liu, L. W., additional, Zhu, T., additional, Li, H. L., additional, Su, H. L., additional, Zhou, X. D., additional, Ruiz Ortiz, M., additional, Mesa Rubio, D., additional, Delgado Ortega, M., additional, Romo Penas, E., additional, Toledano Degado, F., additional, Leon Del Pino, C., additional, Lopez Aguilera, J., additional, Villanueva Fernandez, E., additional, Cejudo Diaz Del Campo, L., additional, Suarez De Lezo, J., additional, Abergel, E., additional, Simon, M., additional, Dehant, P., additional, Bogino, E., additional, Jimenez, M., additional, Verdier, J. C., additional, Chauvel, C., additional, Albertsen, A. E., additional, Nielsen, J. C., additional, Mortensen, P. T., additional, Egeblad, H., additional, Nasr, G. M., additional, Tawfik, S., additional, Omar, A., additional, Olofsson, M., additional, Boman, K., additional, Rezzoug, N., additional, Vaes, B., additional, Degryse, J., additional, Vanoverschelde, J.-L., additional, Pasquet, A. A., additional, Poggio, D., additional, Bonadies, M., additional, Pacher, V., additional, Mazzetti, S., additional, Grillo, M., additional, D'elia, E., additional, Khouri, T., additional, Specchia, G., additional, Mornos, C., additional, Rusinaru, D., additional, Cozma, D., additional, Ionac, A., additional, Petrescu, L., additional, Rotzak, R., additional, Rosenman, Y., additional, Patterson, R. D., additional, Ratnatheepan, S., additional, Bogle, R. G., additional, Goebel, B., additional, Gjesdal, O., additional, Kottke, D., additional, Otto, S., additional, Jung, C., additional, Edvardsen, T., additional, Figulla, H. R., additional, Poerner, T. C., additional, Otsuka, T., additional, Suzuki, M., additional, Yoshikawa, H., additional, Hashimoto, G., additional, Itou, N., additional, Ono, T., additional, Yamamoto, M., additional, Osaki, T., additional, Tsuchida, T., additional, Sugi, K., additional, Wolber, T., additional, Haegeli, L., additional, Huerlimann, D., additional, Brunckhorst, C., additional, Duru, F., additional, Wu, Z. M., additional, Shu, X. H., additional, Dong, L. L., additional, Fan, B., additional, Ge, J. B., additional, Greutmann, M., additional, Tobler, D., additional, Biaggi, P., additional, Mah, M., additional, Crean, A., additional, Oechslin, E. N., additional, Silversides, C. K., additional, Giusca, S., additional, Jurcut, R., additional, Ghiorghiu, I., additional, Coman, I. M., additional, Amzulescu, M., additional, Ionescu, R., additional, Delcroix, M., additional, Voigt, J. U., additional, Piatkowski, R., additional, Kochanowski, J., additional, Scislo, P., additional, Grabowski, M., additional, Marchel, M., additional, Roik, M., additional, Kosior, D., additional, Opolski, G., additional, Maceira Gonzalez, A. M., additional, Cosin-Sales, J., additional, Dalli, E., additional, Igual, B., additional, Monmeneu, J. V., additional, Lopez-Lereu, P., additional, Estornell, J., additional, Ruvira, J., additional, Sotillo, J., additional, Stevanovic, A., additional, Toncev, A., additional, Dimkovic, S., additional, Dekleva, M., additional, Paunovic, N., additional, Toncev, D., additional, Sekularac, N., additional, Yildirimturk, O., additional, Helvacioglu, F. F., additional, Tayyareci, Y., additional, Yurdakul, S., additional, Demiroglu, I. C. C., additional, Aytekin, S., additional, Pinedo Gago, M., additional, Amat Santos, I., additional, Revilla Orodea, A., additional, Lopez Diaz, J., additional, Arnold, R., additional, De La Fuente Galan, L., additional, Recio Platero, A., additional, Gomez Salvador, I., additional, Puerto Sanz, A., additional, San Roman Calvar, J. A., additional, Yotti, R., additional, Bermejo, J., additional, Mombiela, T., additional, Benito, Y., additional, Sanchez, P. L., additional, Solis, J., additional, Prieto, R., additional, Fernandez-Aviles, F., additional, Zilberszac, R., additional, Gabriel, H., additional, Graf, S., additional, Mundigler, G., additional, Maurer, G., additional, Rosenhek, R., additional, Zito, C., additional, Salvia, J., additional, Longordo, C., additional, Donato, D., additional, Alati, E., additional, Miceli, M., additional, Pardeo, A., additional, Arcidiaco, S., additional, Oreto, G., additional, Carerj, S., additional, Hadjimiltiades, S., additional, Sianos, G., additional, Anastasiadis, K., additional, Grosomanidis, V., additional, Efthimiadis, G., additional, Parcharidis, G., additional, Yousry, M., additional, Rickenlund, A., additional, Petrini, J., additional, Gustafsson, T., additional, Liska, J., additional, Hamsten, A., additional, Eriksson, P., additional, Franco-Cereceda, A., additional, Eriksson, M. J., additional, Caidahl, K., additional, Mizia-Stec, K., additional, Pysz, P., additional, Jasinski, M., additional, Drzewiecka-Gerber, A., additional, Krejca, M., additional, Bochenek, A., additional, Wos, S., additional, Gasior, Z., additional, Tendera, M., additional, Niki, K., additional, Sugawara, M., additional, Takamisawa, I., additional, Watanabe, H., additional, Sumiyoshi, T., additional, Hosoda, S., additional, Ida, T., additional, Takanashi, S., additional, Olsen, N. T., additional, Sogaard, P., additional, Jons, C., additional, Mogelvang, R., additional, Larsson, H. B. W., additional, Goetze, J. P., additional, Nielsen, O. W., additional, Fritz-Hansen, T., additional, Sayar, N., additional, Orhan, A. L., additional, Erer, H. B., additional, Eren, M., additional, Atmaca, H., additional, Yilmaz, H. Y., additional, Cakmak, N., additional, Altay, S., additional, Terzi, S., additional, Yesilcimen, K., additional, Garcia Orta, R., additional, Moreno, E., additional, Lopez, M., additional, Uribe, I., additional, Vidal, M., additional, Ruiz-Lopez, M. F., additional, Gonzalez-Molina, M., additional, Oyonarte, J. M., additional, Lopez, S., additional, Azpitarte, J., additional, Szymanski, C., additional, Levine, R. A., additional, Zheng, H., additional, Handschumacher, M. D., additional, Tawakol, A., additional, Hung, J., additional, Le Ven, F., additional, Etienne, Y., additional, Jobic, Y., additional, Frachon, I., additional, Castellant, P., additional, Fatemi, M., additional, Blanc, J. J., additional, Tribouilloy, C., additional, Grigioni, F., additional, Avierinos, J.-F., additional, Barbieri, A., additional, Buiciuc, O., additional, Enriquez-Sarano, M., additional, Said, K., additional, Farag, A. K., additional, El-Ramly, M., additional, Rizk, H., additional, Iorio, A., additional, Pinamonti, B., additional, Bobbo, M., additional, Merlo, M., additional, Massa, L., additional, Faganello, G., additional, Di Lenarda, A., additional, Sinagra, G., additional, Margato, R., additional, Ribeiro, H., additional, Ferreira, C., additional, Matias, A., additional, Fontes, P., additional, Moreira, J. I., additional, Milan, A., additional, Puglisi, E., additional, Magnino, C., additional, Fabbri, A., additional, Leone, D., additional, Vairo, A., additional, Crudo, V., additional, Iannaccone, A., additional, Milazzo, V., additional, Veglio, F., additional, Maroz-Vadalazhskaya, N., additional, Ostrovskiy, I., additional, Imbalzano, E., additional, Saitta, A., additional, Cusma-Piccione, M., additional, Di Bella, G., additional, Nava, R., additional, Ferro, M., additional, Falanga, G., additional, Frigy, A., additional, Buzogany, J., additional, Szabados, C. S., additional, Dan, L., additional, Carasca, E., additional, Ikonomidis, I., additional, Lekakis, J., additional, Tzortzis, S., additional, Kremastinos, D. T., additional, Papadopoulos, C., additional, Paraskevaidis, I., additional, Triantafyllidi, H., additional, Trivilou, P., additional, Venetsanou, K., additional, Anastasiou-Nana, M., additional, Wierzbowska-Drabik, K., additional, Kurpesa, M., additional, Trzos, E., additional, Rechcinski, T., additional, Mozdzan, M., additional, Kasprzak, J. D., additional, Kosmala, W., additional, Kotwica, T., additional, Przewlocka-Kosmala, M., additional, Mysiak, A., additional, Skultetyova, D., additional, Filipova, S., additional, Chnupa, P., additional, Pechlivanidis, G., additional, Dimitroula, H., additional, Tsai, W.-C., additional, Liu, Y.-W., additional, Lin, C.-C., additional, Huang, Y.-Y., additional, Tsai, L.-M., additional, Park, S. M., additional, Kim, Y. H., additional, Shin, S. M., additional, Shim, W. J., additional, Gonzalez Mansilla, A., additional, Torres Macho, J., additional, Sanchez Sanchez, V., additional, Diez, P., additional, Delgado, J., additional, Borruel, S., additional, Saenz De La Calzada, C., additional, Pyxaras, S., additional, Valentincic, M., additional, Barbati, G., additional, Lo Giudice, F., additional, Perkan, A., additional, Magnani, S., additional, Palecek, T., additional, Ambroz, D., additional, Jansa, P., additional, Lindner, J., additional, Vitovec, M., additional, Polacek, P., additional, Jiratova, K., additional, Linhart, A., additional, Baskurt, M., additional, Dogan, G. M., additional, Abaci, O., additional, Kaya, A., additional, Kucukoglu, S., additional, Duszanska, A., additional, Kukulski, T., additional, Skoczylas, I., additional, Majsnerowska, A., additional, Nowowiejska-Wiewiora, A., additional, Streb, W., additional, Szulik, M., additional, Polonski, L., additional, Kalarus, Z., additional, Yerly, P. O., additional, Prella, M., additional, Joly, A., additional, Nicod, L., additional, Aubert, J. D., additional, Aebischer, N., additional, Dores, H., additional, Leal, S., additional, Rosario, I., additional, Correia, M. J., additional, Monge, J., additional, Grilo, A. M., additional, Arroja, I., additional, Fonseca, C., additional, Aleixo, A., additional, Silva, A., additional, Perez-David, E., additional, Sanchez-Alegre, M., additional, Gomez Anta, I., additional, De La Torre, J., additional, Alarcon, J., additional, Garcia Robles, J. A., additional, Lafuente, J., additional, Garcia Alonso, C. J., additional, Vallejo Camazon, N., additional, Gonzalez Guardia, A., additional, Nunez, R., additional, Bosch Carabante, C., additional, Mateu, L., additional, Gual Capllonch, F., additional, Ferrer Sistach, E., additional, Lopez Ayerbe, J., additional, Bayes Genis, A., additional, Tomaszewski, A., additional, Kutarski, A., additional, Tomaszewski, M., additional, Bramos, D., additional, Kalantaridou, A., additional, Takos, D., additional, Skaltsiotis, E., additional, Trika, C., additional, Tsirikos, N., additional, Pamboukas, C., additional, Kottis, G., additional, Toumanidis, S., additional, Aggeli, C., additional, Felekos, I., additional, Roussakis, G., additional, Kazazaki, C., additional, Lampropoulos, K., additional, Lagoudakou, S., additional, Stergiou, C., additional, Pitsavos, C., additional, Stefanadis, C., additional, Kihara, C., additional, Murata, K., additional, Wada, Y., additional, Tanaka, T., additional, Uchida, K., additional, Okuda, S., additional, Susa, T., additional, Matsuzaki, M., additional, Abrahamsson, A., additional, Gudmundsson, P., additional, Brodin, L., additional, Knebel, F., additional, Schattke, S., additional, Sanad, W., additional, Schimke, I., additional, Schroeckh, S., additional, Brechtel, L., additional, Lock, J., additional, Makauskiene, R., additional, Baumann, G., additional, Borges, A. C., additional, Moelmen-Hansen, H. E., additional, Wisloff, U., additional, Aamot, I. L., additional, Stoylen, A., additional, Ingul, C. B., additional, Estensen, M.-E., additional, Beitnes, J. O., additional, Grindheim, G., additional, Henriksen, T., additional, Aaberge, L., additional, Smiseth, O. A., additional, Gullestad, L., additional, Aakhus, S., additional, Agoston, G., additional, Moggi Pignone, A., additional, Capati, E., additional, Badano, L., additional, Moreo, A., additional, Bombardieri, S., additional, Varga, A., additional, Carrideo, M., additional, Faricelli, S., additional, Corazzini, A., additional, Ippedico, R., additional, Ruggieri, B., additional, Di Blasio, A., additional, D'angelo, E., additional, Di Baldassarre, A., additional, Ripari, P., additional, Gallina, S., additional, Kentrschynskyj, A., additional, Hylander, B., additional, Jacobson, S., additional, Pagels, A., additional, Dumitrescu, S. I., additional, Tintoiu, I., additional, Greere, V., additional, Cristian, G., additional, Chiriac, L., additional, Pinte, F., additional, Droc, I., additional, Neagoe, G., additional, Stanciu, S., additional, Voicu, V. A., additional, Kuch-Wocial, A., additional, Pruszczyk, P., additional, Szmigielski, C. A., additional, Szulc, M., additional, Styczynski, G., additional, Sinski, M., additional, Kaczynska, A., additional, Ryabikov, A., additional, Malyutina, S., additional, Halcox, J., additional, Bobak, M., additional, Nikitin, Y. U., additional, Marmot, M., additional, Barbosa, D., additional, Kiss, G., additional, Orderud, F., additional, Amundsen, B., additional, Jasaityte, R., additional, Loeckx, D., additional, Claus, P., additional, Torp, H., additional, D'hooge, J., additional, Kuhl, J. T., additional, Lonborg, J., additional, Fuchs, A., additional, Andersen, M., additional, Vejlstrup, N., additional, Engstrom, T., additional, Moller, J. E., additional, Kofoed, K. F., additional, Smith, L. A., additional, Bhan, A., additional, Paul, M., additional, Monaghan, M. J., additional, Zaborska, B., additional, Stec, S., additional, Sikora-Frac, M., additional, Krynski, T., additional, Kulakowski, P., additional, Pushparajah, K., additional, Dashwood, D., additional, Barlow, A., additional, Nugent, K., additional, Miller, O., additional, Simpson, J., additional, Valeur, N., additional, Ersboll, M. K., additional, Kjaergaard, J., additional, Greibe, R., additional, Risum, N., additional, Hassager, C., additional, Kober, L., additional, Popovic, D., additional, Nedeljkovic, I., additional, Petrovic, M., additional, Vujisic-Tesic, B., additional, Arandjelovic, A., additional, Stojiljkovic, S., additional, Jakovljevic, B., additional, Damjanovic, S., additional, Ostojic, M., additional, Agrios, I. A., additional, Bramos, D. B., additional, Skaltsiotis, H. S., additional, Takos, D. T., additional, Kaladaridis, A., additional, Vasiladiotis, N. V., additional, Kottis, G. K., additional, Antoniou, A. A., additional, Pamboucas, C. P., additional, Toumanidis, S. T. T., additional, Locorotondo, G., additional, Porto, I., additional, Paraggio, L., additional, Fedele, E., additional, Barchetta, S., additional, De Caterina, A. R., additional, Rebuzzi, A. G., additional, Crea, F., additional, Galiuto, L., additional, Lipiec, P., additional, Szymczyk, E., additional, Michalski, B., additional, Wozniakowski, B., additional, Stefanczyk, L., additional, Rotkiewicz, A., additional, Shim, A., additional, Vainer, J., additional, Habets, J., additional, Lousberg, A., additional, Pont De, C., additional, Waltenberger, J., additional, Farouk, H., additional, Heshmat, H., additional, Adel, A., additional, El Chilali, K., additional, Baghdady, Y., additional, Sorour, K., additional, Gustafsson, U., additional, Larsson, M., additional, Bjallmark, A., additional, Lindqvist, P., additional, A'roch, R., additional, Haney, M., additional, Waldenstrom, A., additional, Mladenovic, Z., additional, Tavciovski, D., additional, Mijailovic, Z., additional, Djordjevic - Dikic, A., additional, Obradovic, S., additional, Matunovic, R., additional, Jovic, Z., additional, Djuric, P., additional, Aase, S., additional, Dalen, H., additional, Sarkola, T., additional, Redington, A. N., additional, Keeley, F., additional, Bradley, T., additional, Jaeggi, E., additional, and Sahlen, H., additional

Published
2010
Full Text
View/download PDF

30. An Intermediate Framework for Unifying and Automating Mobile Communication Systems.

Author

Gaiti, Dominique, Pujolle, Guy, Al-Shaer, Ehab, Calvert, Ken, Dobson, Simon, Leduc, Guy, Martikainen, Olli, Koumoutsos, G., Lampropoulos, K., Efthymiopoulos, N., Christakidis, A., Denazis, S., and Thramboulidis, K.

Abstract

In the last few years we are witnessing a rapid growth in the mobile use of the internet and services like telephony. Mobility offers a great deal of advantages to end users but has also restrictions due to heterogeneity of networks, protocols and mobile devices with limited capabilities. In that we can add the need for manual interaction with service providers which costs in time and flexibility. We propose a framework that solves major mobility issues like connection maintenance, roaming, automated service selection regardless the underlying devices, protocols, providers and services. We describe important steps that will automate procedures and became the bases for an autonomic mobile environment transparent to the end user. Keywords: Mobile Router, SLA, negotiation, matchmaking, ontologies, net-work mobility, addressing, roaming. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

32. End Node Security and Trust vulnerabilities in the Smart City Infrastructure

Author

Fournaris Apostolos P., Lampropoulos Konstantinos, and Koufopavlou Odysseas

Subjects
Engineering (General). Civil engineering (General), TA1-2040
Abstract

As cities gradually introduce intelligence in their core services and infrastructure thus becoming “smart cities”, they are deploying new Information Technology devices in the urban grid that are interconnected to a broad network. The main focus of widely implemented smart cities' services was the operation of sensors and smart devices across city areas that need low energy consumption and high connectivity. However, as 5G technologies are gradually been adopted in the smart city infrastructure thus solving that problem, the fundamental issue of addressing security becomes dominant. While latest network topologies and standards include security functions thus giving an illusion of security, there is little focus on the fact that many smart city end nodes cannot realize all security specifications without additional help. In this paper, we discuss briefly smart city security issues and focus on problem and security requirement that need to be address in the smart city end nodes, the sensors and actuators deployed within the city's grid. In this paper, attacks that cannot be thwarted by traditional cybersecurity solutions are discussed and countermeasures based on hardware are suggested in order to achieve a high level of trust. Also, the danger of microarchitectural and side channel attacks on these devices is highlighted and protection approaches are discussed.

Published
2018
Full Text
View/download PDF

34. A Questionnaire Model for Cybersecurity Maturity Assessment of Critical Infrastructures

Author

Yigit Ozkan, B., Spruit, M, Fournaris, A., Lampropoulos, K., Tordera, E., Sub Natural Language Processing, Sub Organization and Information, Natural Language Processing, and Organization and Information

Subjects
021110 strategic, defence & security studies, Cybersecurity, 0211 other engineering and technologies, 020207 software engineering, 02 engineering and technology, Service provider, Assessment, Computer security, computer.software_genre, Critical infrastructure, Sustainability, Capability, 0202 electrical engineering, electronic engineering, information engineering, Improvement, Maturity assessment, Business, Everyday life, computer
Abstract

Critical infrastructures are important assets for everyday life and wellbeing of the people. People can be effected dramatically if critical infrastructures are vulnerable and not protected against various threats. Given the increasing cybersecurity risks and the large impact that these risks may bring to the critical infrastructures, assessing and improving the cybersecurity capabilities of the service providers and the administrators is crucial for sustainability. This research aims to provide a questionnaire model for assessing and improving cybersecurity capabilities based on industry standards. Another aim of this research is to provide service providers and the administrators of the critical infrastructures a personalized guidance and an implementation plan for cybersecurity capability improvement.

Full Text
View/download PDF

39. Apical ballooning syndrome: a case report

Author

Lampropoulos Konstantinos M, Kotsas Dimitrios, and Iliopoulos Themistoklis A

Subjects
Apical ballooning syndrome, Stress cardiomyopathy, Acute coronary syndrome, Medicine, Biology (General), QH301-705.5, Science (General), Q1-390
Abstract

Abstract Background Apical ballooning syndrome mimics acute coronary syndromes and it is characterized by reversible left ventricular apical ballooning in the absence of angiographically significant coronary artery stenosis. Case presentation This is a case of a 40-year-old Caucasian male without any health related problems that was submitted to an urgent coronary angiography because of acute chest pain and marked precordial T-wave inversions suggestive of acute myocardial ischemia. Coronary angiography showed no significant stenosis of the coronary arteries. Left ventriculography showed systolic apical ballooning with mild basal hypercontraction. Conclusion Physicians should be aware of the presentation of apical ballooning syndrome, and the chest pain after following acute stress should not be readily attributed to anxiety.

Published
2012
Full Text
View/download PDF

41. Visualization of the intracavitary blood flow in systemic ventricles of Fontan patients by contrast echocardiography using particle image velocimetry

Author

Lampropoulos Konstantinos, Budts Werner, Van de Bruaene Alexander, Troost Els, and van Melle Joost P

Subjects
Fontan patients, Vortex, Contrast echocardiography, Particle image velocimetry, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract Background Flow patterns in univentricular hearts may have clinical value. Therefore, it is our objective to asses and characterize vortex flow patterns with Fontan circulation in comparison with healthy controls. Methods Twenty-three patients (8 Fontan and 15 normal patients) underwent echocardiography with intravenous contrast agent (Sonovue®) administration. Dedicated software was used to perform particle image velocimetry (PIV) and to visualize intracavitary flow in the systemic ventricles of the patients. Vortex parameters including vortex depth, length, width, and sphericity index were measured. Vortex pulsatility parameters including relative strength, vortex relative strength, and vortex pulsation correlation were also measured. Results The data from this study show that it is feasible to perform particle velocimetry in Fontan patients. Vortex length (VL) was significantly lower (0.51 ± 0.09 vs 0.65 ± 0.12, P = 0.010) and vortex width (VW) (0.32 ± 0.06 vs 0.27 ± 0.04, p = 0.014), vortex pulsation correlation (VPC) (0.26 ± 0.25 vs -0.22 ± 0.87, p = 0.05) were significantly higher in Fontan patients. Sphericity index (SI) (1.66 ± 0.48 vs 2.42 ± 0.62, p = 0.005), relative strength (RS) (0.77 ± 0.33 vs 1.90 ± 0.47, p = 0.0001), vortex relative strength (VRS) (0.18 ± 0.13 vs 0.43 ± 0.14, p = 0.0001) were significantly lower in the Fontan patients group. Conclusions PIV using contrast echocardiography is feasible in Fontan patients. Fontan patients had aberrant flow patterns as compared to normal hearts in terms of position, shape and sphericity of the main vortices. The vortex from the Fontan group was consistently shorter, wider and rounder than in controls. Whether vortex characteristics are related with clinical outcome is subject to further investigation.

Published
2012
Full Text
View/download PDF

42. Early bare-metal stent thrombosis presenting with cardiogenic shock: a case report

Author

Lampropoulos Konstantinos M, Iliopoulos Themistoklis A, and Budts Werner

Subjects
Medicine
Abstract

Abstract Introduction Although stents have improved the safety and efficacy of percutaneous coronary interventions, coronary stent thrombosis remains a serious complication. Case presentation We present the case of a 64-year-old Caucasian man from Greece, with symptoms and electrocardiographic findings suggestive of acute inferior myocardial infarction, who complained of chest pain and rapidly developed cardiogenic shock 48 hours after primary percutaneous coronary intervention. Conclusion The most common cause of early bare-metal stent thrombosis is stent malapposition. Intravascular ultrasound is the preferred method to recognize predictors of coronary events that are not detected by angiography.

Published
2011
Full Text
View/download PDF

43. The THREAT-ARREST Cyber-Security Training Platform

Author

Ernesto Damiani, George Spanoudakis, Dirk Wortmann, Kristian Beckers, Othonas Soultatos, George Bravos, Konstantinos Fysarakis, Hristo Koshutanski, Menelaos Ioannidis, Fournaris, A. P., Athanatos, M., Lampropoulos, K., Ioannidis, S., Hatzivasilis, G., Damiani, E., Abie, H., Ranise, S., Verderame, L., Siena, A., and Garcia-Alfaro, J.

Subjects
QA75, SIMPLE (military communications protocol), Computer science, 020207 software engineering, 02 engineering and technology, Computer security, computer.software_genre, Training (civil), Smart grid, Sustainability, 0202 electrical engineering, electronic engineering, information engineering, 020201 artificial intelligence & image processing, Training program, computer
Abstract

Cyber security is always a main concern for critical infrastructures and nation-wide safety and sustainability. Thus, advanced cyber ranges and security training is becoming imperative for the involved organizations. This paper presets a cyber security training platform, called THREAT-ARREST. The various platform modules can analyze an organization’s system, identify the most critical threats, and tailor a training program to its personnel needs. Then, different training programmes are created based on the trainee types (i.e. administrator, simple operator, etc.), providing several teaching procedures and accomplishing diverse learning goals. One of the main novelties of THREAT-ARREST is the modelling of these programmes along with the runtime monitoring, management, and evaluation operations. The platform is generic. Nevertheless, its applicability in a smart energy case study is detailed.

Published
2020
Full Text
View/download PDF

44. Cardiac contractility modulation in patients with heart failure - A review of the literature.

Author

Bazoukis G, Saplaouras A, Efthymiou P, Yiannikourides A, Liu T, Letsas KP, Efremidis M, Lampropoulos K, Xydonas S, Tse G, and Armoundas AA

Subjects
Humans, Ventricular Function, Left physiology, Cardiac Resynchronization Therapy methods, Quality of Life, Heart Failure physiopathology, Heart Failure therapy, Myocardial Contraction physiology, Stroke Volume physiology
Abstract

Experimental in vivo and in vitro studies showed that electric currents applied during the absolute refractory period can modulate cardiac contractility. In preclinical studies, cardiac contractility modulation (CCM) was found to improve calcium handling, reverse the foetal myocyte gene programming associated with heart failure (HF), and facilitate reverse remodeling. Randomized control trials and observational studies have provided evidence about the safety and efficacy of CCM in patients with HF. Clinically, CCM therapy is indicated to improve the 6-min hall walk, quality of life, and functional status of HF patients who remain symptomatic despite guideline-directed medical treatment without an indication for cardiac resynchronization therapy (CRT) and have a left ventricular ejection fraction (LVEF) ranging from 25 to 45%. Although there are promising results about the role of CCM in HF patients with preserved LVEF (HFpEF), further studies are needed to elucidate the role of CCM therapy in this population. Late gadolinium enhancement (LGE) assessment before CCM implantation has been proposed for guiding the lead placement. Furthermore, the optimal duration of CCM application needs further investigation. This review aims to present the existing evidence regarding the role of CCM therapy in HF patients and identify gaps and challenges that require further studies., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

45. When anticoagulation management in atrial fibrillation becomes difficult: Focus on chronic kidney disease, coagulation disorders, and cancer.

Author

Papakonstantinou PE, Kalogera V, Charitos D, Polyzos D, Benia D, Batsouli A, Lampropoulos K, Xydonas S, Gupta D, and Lip GYH

Subjects
Humans, Anticoagulants adverse effects, Administration, Oral, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Stroke chemically induced, Stroke drug therapy, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic drug therapy, Renal Insufficiency, Chronic chemically induced, Blood Coagulation Disorders, Neoplasms complications, Neoplasms drug therapy
Abstract

Anticoagulation therapy (AT) is fundamental in atrial fibrillation (AF) treatment but poses challenges in implementation, especially in AF populations with elevated thromboembolic and bleeding risks. Current guidelines emphasize the need to estimate and balance thrombosis and bleeding risks for all potential candidates of antithrombotic therapy. However, administering oral AT raises concerns in specific populations, such as those with chronic kidney disease (CKD), coagulation disorders, and cancer due to lack of robust data. These groups, excluded from large direct oral anticoagulants trials, rely on observational studies, prompting physicians to adopt individualized management strategies based on case-specific evaluations. The scarcity of evidence and specific guidelines underline the need for a tailored approach, emphasizing regular reassessment of risk factors and anticoagulation drug doses. This narrative review aims to summarize evidence and recommendations for challenging AF clinical scenarios, particularly in the long-term management of AT for patients with CKD, coagulation disorders, and cancer., Competing Interests: Declaration of competing interest GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871., (Copyright © 2024 Elsevier Ltd. All rights reserved.)

Published
2024
Full Text
View/download PDF

46. [Régurgitation mitrale sévère due à la sarcoïdose cardiaque : une présentation clinique inhabituelle ; une étude de cas et des recherches antérieures].

Author

Polyzos D, Patavoukas G, Lykoudis A, Mamaloukaki M, and Lampropoulos K

Subjects
Humans, Mitral Valve Insufficiency complications, Heart Failure complications, Sarcoidosis complications
Abstract

Sarcoidosis is a granulomatous inflammatory disease that may involve multiple organ systems, including the heart. Cardiac manifestations are not rare and include atrial and ventricular arrhythmias, conduction abnormalities, congestive heart failure, valvular dysfunction, pericarditis, and sudden death. Although, cardiac sarcoidosis (CS) remains a diagnostic and therapeutic challenge. This article describes a case of a patient with a history of pulmonary sarcoidosis who presented with congestive heart failure, on the basis of severe mitral regurgitation secondary to cardiac infiltration and summarizes the published evidence regarding CS and mitral regurgitation., Competing Interests: Conflicts of interest The authors declare no conflict of interest., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)

Published
2024
Full Text
View/download PDF

47. Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients.

Author

Valachis A, Biganzoli L, Christopoulou A, Fjermeros K, Fountzila E, Geisler J, Gomez-Bravo R, Karihtala P, Kosmidis P, Koutras A, Linardou H, Lindman H, Martínez-Ballestero I, Rodríguez AB, Meattini I, Munoz-Mateu M, Othman M, Psyrri A, Risi E, Schiza A, Spathas N, Utriainen M, Visani L, Ballesteros S, Basdekis I, Hay SD, Fotis T, Fricker S, de Graaf G, Jenset M, Kanters T, Lampropoulos K, Markou C, Mastoraki K, Nanou C, Reales Aviles JM, Santaholma M, and Kosmidis T

Subjects
Humans, Female, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 metabolism, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Geriatric Assessment
Abstract

Current evidence from both randomized trials and real-world studies suggests that older patients with advanced hormone receptor-positive/HER2-negative (HR+/HER2) breast cancer derive clinical benefit from the addition of CDK4/6 inhibitors to endocrine therapy. However, a higher risk for adverse events due to CDK4/6 inhibitors among older patients is evident, leading to a trend of initiating CDK4/6 inhibitors at lower dose in clinical practice, though without evidence. The aim of the IMPORTANT-trial, a pragmatic, multinational, open-label, partly decentralized randomized trial is to investigate whether lower starting dose of CDK4/6 inhibitors combined with endocrine therapy is comparable to full dose in older (≥70 years old) patients with advanced HR+/HER2- breast cancer who are assessed as vulnerable or frail based on comprehensive geriatric assessment. Clinical Trial Registration: NCT06044623 (ClinicalTrials.gov); Registration date: 13 September 2023.

Published
2024
Full Text
View/download PDF

49. Optimal Anticoagulation on TAVI Patients Based on Thrombotic and Bleeding Risk and the Challenge Beyond: A Systematic Review and Meta-Analysis.

Author

Tsoumas I, Oz A, and Lampropoulos K

Subjects
Humans, Anticoagulants adverse effects, Hemorrhage etiology, Rivaroxaban, Treatment Outcome, Platelet Aggregation Inhibitors adverse effects, Thrombosis etiology, Thrombosis prevention & control, Transcatheter Aortic Valve Replacement adverse effects
Abstract

Transcatheter Aortic Valve Replacement (TAVR) has been established as the treatment of choice for symptomatic aortic stenosis, while it is expanding in all risk-related group categories of patients, gaining gradually ground over the surgical approach. However, complications and adverse events are yet to be effectively limited and diminished with thrombotic and hemorrhagic events being rooted as a crucial topic of discussion. Favorable anticoagulation pharmacotherapy options are constantly being revised and tested, whilst guidelines are being modified to meet current clinical evidence. This review aims to systematically assess already existing guidelines on anticoagulation in post-TAVI patients and examine novel regimens for the specific use, like apixaban, rivaroxaban, and other anticoagulants, essentially constructing a holistic point of view on future progress on this matter. The added complexity brought by coagulation-affecting comorbidities such as atrial fibrillation, coronary artery disease, and more contributes to the direct association of the topic to the quality of healthcare as a public service. The literature was systematically searched to examine the effectiveness and safety of various anticoagulation treatments and cross-evaluate them based on the according category of patients that were assigned to. Clinical trials, observational studies and systematic reviews were included and, eventually, conclusive remarks and future considerations were developed and presented. In the category of patients without prior indication to anticoagulation, SAPT was proven safer and still effective, when antiplatelet therapies were compared, while a comparison of antiplatelet versus anticoagulation strategies noted the first one, with limited data, as the optimal one. Lastly, direct oral anticoagulants were shown to be safe substitutes for vitamin K antagonists for patients with prior indication to anticoagulation., (Copyright © 2023 Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

50. Aortic Stiffness: A Major Risk Factor for Multimorbidity in the Elderly.

Author

Triposkiadis F, Xanthopoulos A, Lampropoulos K, Briasoulis A, Sarafidis P, Skoularigis J, and Boudoulas H

Abstract

Multimorbidity, the coexistence of multiple health conditions in an individual, has emerged as one of the greatest challenges facing health services, and this crisis is partly driven by the aging population. Aging is associated with increased aortic stiffness (AoStiff), which in turn is linked with several morbidities frequently affecting and having disastrous consequences for the elderly. These include hypertension, ischemic heart disease, heart failure, atrial fibrillation, chronic kidney disease, anemia, ischemic stroke, and dementia. Two or more of these disorders (multimorbidity) often coexist in the same elderly patient and the specific multimorbidity pattern depends on several factors including sex, ethnicity, common morbidity routes, morbidity interactions, and genomics. Regular exercise, salt restriction, statins in patients at high atherosclerotic risk, and stringent blood pressure control are interventions that delay progression of AoStiff and most likely decrease multimorbidity in the elderly.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results